The estimated Net Worth of Donald W. Glazer is at least $21.8 Million dollars as of 29 August 2018. Mr. Glazer owns over 2,000 units of BeiGene Ltd stock worth over $2,826,032 and over the last 8 years he sold BGNE stock worth over $18,575,909. In addition, he makes $363,000 as Non-Executive Independent Director at BeiGene Ltd.
Sign up
Mr. Glazer BGNE stock SEC Form 4 insiders trading
Donald has made over 13 trades of the BeiGene Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of BGNE stock worth $1,698,400 on 19 May 2020.
The largest trade he's ever made was selling 67,252 units of BeiGene Ltd stock on 19 September 2016 worth over $2,113,058. On average, Donald trades about 14,581 units every 45 days since 2016. As of 29 August 2018 he still owns at least 13,384 units of BeiGene Ltd stock.
You can see the complete history of Mr. Glazer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Donald Glazer biography
Donald Wayne Glazer J.D. serves as Non-Executive Independent Director of the Company. Mr. Glazer has served as a member of the Board of Trustees of GMO Trust, a mutual fund group, since 2000 and as the Chairman of the Board of GMO Trust since 2005. Mr. Glazer was a Co-Founder and Secretary, and from 2002 until 2010, Vice Chairman, of Provant, Inc., a provider of performance improvement training solutions. From 1992 to 1995 Mr. Glazer was President of Mugar/Glazer Holdings and from 1992 to 1993 served as Vice Chairman—Finance of New England Television Corp and WHDH-TV, Inc. From 1997 to the present, Mr. Glazer has served as Advisory Counsel to Goodwin Procter LLP. From 1970 to 1978 Mr. Glazer was an associate and from 1978 to 1992 a partner at Ropes & Gray LLP, a Boston law firm. At Ropes & Gray, Mr. Glazer chaired the firm’s Emerging Companies Group. Mr. Glazer was also a Lecturer in Law at Harvard Law School from 1978 to 1991, teaching a course called The Business Lawyer. Mr. Glazer is a former member of the boards of directors of Environics Inc.; Kronos Incorporated; Reflective Technologies, Inc.; and Teleco Oilfield Services Inc. Mr. Glazer received his A.B. from Dartmouth College in June, 1966; J.D. from Harvard Law School in June, 1969, where he was an editor of the Harvard Law Review; and L.L.M. from the University of Pennsylvania Law School in May, 1970. Additionally, Mr. Glazer is a co-author of both Glazer and FitzGibbon on Legal Opinions, Third Edition (Aspen Publishers) and Massachusetts Corporation Law & Practice, Second Edition.
What is the salary of Donald Glazer?
As the Non-Executive Independent Director of BeiGene Ltd, the total compensation of Donald Glazer at BeiGene Ltd is $363,000. There are 13 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.
How old is Donald Glazer?
Donald Glazer is 75, he's been the Non-Executive Independent Director of BeiGene Ltd since 2013. There are no older and 21 younger executives at BeiGene Ltd.
What's Donald Glazer's mailing address?
Donald's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Insiders trading at BeiGene Ltd
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., and Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
What does BeiGene Ltd do?
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
What does BeiGene Ltd's logo look like?
Complete history of Mr. Glazer stock trades at BeiGene Ltd
BeiGene Ltd executives and stock owners
BeiGene Ltd executives and other stock owners filed with the SEC include:
-
John Oyler,
Co-Founder, Executive Chairman of the Board, Chief Executive Officer -
Xiaodong Wang,
Co-Founder, Non-Executive Director -
Dr. Xiaodong Wang Ph.D.,
Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director -
John V. Oyler,
Co-Founder, Exec. Chairman & CEO -
Dr. Xiaobin Wu Ph.D.,
Pres, COO & GM of China -
Wang Lai,
Global Head of R&D -
Dr. Edna Huang M.D.,
Chief Medical Officer of Hematology -
Dr. Jane Edna Huang M.D.,
Chief Medical Officer of Hematology -
Dr. Heng Liang,
CFO & Chief Strategy Officer -
Thomas Malley,
Non-Executive Independent Director -
Qingqing YI,
Non-Executive Independent Director -
Timothy Chen,
Non-Executive Independent Director -
Jing-Shyh Su,
Non-Executive Independent Director -
Donald Glazer,
Non-Executive Independent Director -
Ranjeev Krishana,
Non-Executive Independent Director -
Michael Goller,
Non-Executive Independent Director -
Corazon Sanders,
Non-Executive Independent Director -
Anthony Hooper,
Non-Executive Director -
Hing Ling Chau,
Company Secretary -
Jane Huang,
Chief Medical Officer, Hematology -
Xiaobin Wu,
General Manager - China, President -
Kevin C. Mannix,
Sr. VP of Investor Relations. -
Mi Zhou,
Sr. Director of Investor Relations -
Julia Wang,
CFO & Principal Accounting Officer -
Diana Lee Francis,
VP and Global Head of Quality & Regulatory Compliance -
Scott Samuels,
Sr. VP & Gen. Counsel -
Craig West CFA,
Sr. Director of Investor Relations -
Michael Garvey,
Global Head of Technical Operations -
Daniel Maller,
VP of Fin. & Accounting -
Jianxin Yang,
Sr. VP, Head of Clinical Dev. -
Amy C. Peterson,
CMO, Immuno-oncology -
Ji Li,
EVP and Gl. Head of Bus. Dev. -
Investment Management, Ltd....,
10% owner -
Rui Rong Yuan,
Chief Medical Officer -
Ke Tang,
Director -
Bros. Advisors Lp Baker Bro...,
-
Biotech Investment Ltd Cpe ...,
-
Wendy Xiaojun Yan,
Sr. VP, Head of Reg. Affairs -
& Co., Inc.Merck Sharp & Do...,
-
Chan Henry Lee,
SVP, General Counsel -
Bros. Advisors Lp14159, L.P...,
-
Bros. Advisors Lp667, L.P.B...,
-
Howard Liang,
CFO & Chief Strategy Officer -
Inc Amgen,
10% owner -
Lai Wang,
Global Head of R&D -
Olivier Brandicourt,
Director -
Julia Aijun Wang,
Chief Financial Officer -
Margaret Dugan,
Director -
Advisors, Ltd.Hillhouse Inv...,
-
Bros. Advisors Lp667, L.P.B...,
-
Titus B. Ball,
Principal Accounting Officer -
Aaron Rosenberg,
Chief Financial Officer